Vorasidenib has a molecular formula of C14H13ClF6N6 and a molecular weight of approximately 414.74 g/mol. It is associated with mutant IDH1 research, mutant IDH2 research, isocitrate dehydrogenase signaling, oncometabolite research, 2-hydroxyglutarate pathways, glioma research, brain tumor biology, and targeted oncology drug development.
Vorasidenib is associated with inhibition of mutant isocitrate dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes. Mutations in IDH1 and IDH2 are associated with abnormal production of the oncometabolite 2-hydroxyglutarate, commonly abbreviated as 2-HG.
Dual inhibition of mutant IDH1 and mutant IDH2 is studied in relation to reduction of abnormal 2-HG production, cellular differentiation pathways, epigenetic regulation, tumor cell metabolism, and IDH-mutant glioma biology.
Vorasidenib is commonly described as a brain-penetrant dual mutant IDH1/IDH2 inhibitor and is associated with central nervous system and neuro-oncology pharmaceutical research.
Vorasidenib is also identified in research and development literature by the code AG-881.
Vorasidenib should be distinguished from Vorasidenib Citrate and other salt or formulation forms according to the applicable product identity, molecular composition, salt form, solid-state characteristics, and approved product specifications.
Product identity, stereochemical characteristics, solid-state form, polymorphic characteristics, particle properties, impurity profile, residual solvents, and applicable analytical specifications should be confirmed against the applicable Certificate of Analysis (COA) and approved product specification.
Swapnroop Drugs & Pharmaceuticals is a trusted Vorasidenib API manufacturer and supplier in India, supplying quality-focused active pharmaceutical ingredients for mutant IDH inhibitor pharmaceutical development, neuro-oncology applications, glioma research, 2-hydroxyglutarate pathway studies, brain-penetrant oncology drug development, analytical development, and global pharmaceutical requirements.
Our Vorasidenib API is supplied with a strong commitment to quality, regulatory compliance, product consistency, comprehensive documentation, and dependable worldwide distribution.
We support customer-specific specifications while meeting applicable pharmaceutical quality, analytical, and documentation requirements.
Vorasidenib is a dual mutant IDH1 and IDH2 inhibitor active pharmaceutical ingredient associated with isocitrate dehydrogenase enzyme inhibition, 2-hydroxyglutarate metabolism, oncometabolite pathways, cellular differentiation, glioma biology, and targeted neuro-oncology pharmaceutical development.
It is commonly associated with pharmaceutical research and development involving mutant IDH1 enzymes, mutant IDH2 enzymes, IDH-mutant glioma, 2-HG production, cancer metabolism, epigenetic regulation, astrocytoma research, oligodendroglioma research, and brain-penetrant targeted oncology drug development.
Vorasidenib research
Vorasidenib API research
AG-881 research
AG881 research
IDH inhibitor research
IDH1 inhibitor research
IDH2 inhibitor research
Dual IDH inhibitor research
Dual IDH1 IDH2 inhibitor research
Mutant IDH inhibitor research
Mutant IDH1 research
Mutant IDH2 research
mIDH1 research
mIDH2 research
mIDH1/2 inhibitor research
Isocitrate dehydrogenase research
Isocitrate dehydrogenase inhibitor research
IDH enzyme research
IDH enzyme inhibition research
IDH mutation research
IDH-mutant tumor research
IDH-mutant cancer research
IDH-mutant glioma research
2-Hydroxyglutarate research
2-HG research
D-2-hydroxyglutarate research
Oncometabolite research
Oncometabolite pathway research
Cancer metabolism research
Tumor metabolism research
Metabolic oncology research
Cellular metabolism research
Cellular differentiation research
Tumor cell differentiation research
Epigenetic regulation research
Epigenetic pathway research
DNA methylation research
Cancer epigenetics research
Glioma research
Low-grade glioma research
Grade 2 glioma research
Diffuse glioma research
Brain tumor research
Brain cancer research
Neuro-oncology research
Central nervous system tumor research
CNS tumor research
Astrocytoma research
Grade 2 astrocytoma research
Oligodendroglioma research
Grade 2 oligodendroglioma research
Glioma cell biology research
Brain-penetrant drug research
Blood-brain barrier penetration research
CNS drug research
Molecular oncology research
Tumor biology research
Cancer biology research
Targeted cancer therapy research
Targeted oncology research
IDH inhibitor drug development
Dual IDH inhibitor drug development
Glioma drug development
Neuro-oncology drug development
Brain tumor drug development
Targeted therapy drug development
Small molecule drug development
Pharmaceutical formulation development
Oral formulation development
Tablet formulation development
Active pharmaceutical ingredient development
Pharmaceutical analytical research
Quality control laboratories
Analytical method development
Impurity profiling studies
Residual solvent analysis
Stability studies
Reference standard applications
Pharmaceutical R&D
Contract manufacturing support
Research and development applications
Trusted API & Pharmaceutical Raw Material Supplier
Quality-Focused Pharmaceutical Materials
COA, MOA & Technical Documentation Support
Customer-Specific Specifications
Reliable Global Supply Chain
Competitive Commercial Pricing
Specialized Oncology & Mutant IDH Inhibitor API Supply
Customized Packaging Solutions
Export Documentation Assistance
Professional Technical Support
Timely Worldwide Delivery
Swapnroop Drugs & Pharmaceuticals supplies Vorasidenib API to:
Pharmaceutical Manufacturers
Oncology Pharmaceutical Companies
Neuro-Oncology Pharmaceutical Companies
IDH Inhibitor Drug Developers
Mutant IDH1 Inhibitor Drug Developers
Mutant IDH2 Inhibitor Drug Developers
Dual IDH Inhibitor Drug Developers
Glioma Drug Developers
Brain Tumor Pharmaceutical Companies
IDH-Mutant Glioma Research Organizations
Glioma Research Organizations
Low-Grade Glioma Research Organizations
Astrocytoma Research Organizations
Oligodendroglioma Research Organizations
Neuro-Oncology Research Organizations
Brain Tumor Research Organizations
Cancer Metabolism Research Organizations
Oncometabolite Research Organizations
2-Hydroxyglutarate Research Organizations
Epigenetic Research Organizations
Molecular Oncology Research Organizations
Cancer Biology Research Organizations
Tumor Biology Research Organizations
CNS Drug Developers
Targeted Therapy Drug Developers
Generic Pharmaceutical Companies
Oral Formulation Manufacturers
Tablet Formulation Manufacturers
API Formulation Companies
Pharmaceutical Development Companies
Medicinal Chemistry Research Organizations
Biotechnology Companies
Research Organizations
Contract Research Organizations (CROs)
Contract Development & Manufacturing Organizations (CDMOs)
Pharmaceutical R&D Centers
Universities & Research Institutes
Analytical Laboratories
International Pharmaceutical Buyers
Located in Chhatrapati Sambhajinagar (Aurangabad), Maharashtra, India, we support domestic and international pharmaceutical supply requirements with efficient logistics and export documentation assistance.
We support Vorasidenib API enquiries from pharmaceutical companies, oncology pharmaceutical organizations, neuro-oncology drug developers, mutant IDH inhibitor pharmaceutical companies, glioma research organizations, brain tumor research organizations, formulation manufacturers, medicinal chemistry organizations, biotechnology companies, research institutes, analytical laboratories, and international pharmaceutical buyers across India and global markets.
Our team assists customers with:
Product Specifications
Certificate of Analysis (COA)
Technical Documentation
Packaging Options
Commercial Quotations
Export Documentation
Worldwide Shipping Support
Supply enquiries are subject to product availability, customer verification, intended end-use, intellectual property considerations, applicable pharmaceutical regulations, destination-country requirements, and regulatory requirements.
Get Bulk Quote via WhatsApp